---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036296"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:09:05.368428+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics reports Q4 2024 net loss of $23.8M; cash runway extended to mid-2026 after $48.9M offering

## Summary
- Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
- Cash and investments $61.4M at Dec 31, 2024; after $48.9M March 2025 offering, runway into mid-2026.
- Dosing initiated in Cohort 2 (6E13 vg/kg) of MyPEAK-1 Phase 1b/2 trial for TN-201; Cohort 1 data accepted as ACC late-breaker.
- First patient dosed in RIDGE-1 Phase 1b trial for TN-401; initial data expected in 2H25; CIRM awarded $8M grant.
- Hiro Higa promoted to SVP, Finance and interim principal accounting officer.

## SEC filing metadata
- accession: 0000950170-25-036296
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017025036296/0000950170-25-036296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017025036296/tnya-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036296
- JSON: https://secwatch.observer/filing/0000950170-25-036296.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.